Expiration date: 03/2025

The composition and form of issue:

Capsules. 1 capsulecontains:

the dried aqueous-alcoholic extract of bilberry fruit (Vaccinium myrtillus), containing 25% anthocyanidins 177 mg

excipients: soybean oil hydrogenated fats of vegetable gelatin glycerol iron oxide red iron oxide black sodium ethyl-p-oxybenzoic sodium propilparagidroksibenzoat 

blistere in 20 PCs. in cardboard pack 1 blister.

Description pharmaceutical form:

Soft gelatin capsules are oval-shaped brown.

The contents of capsules — oily mass black.

Description pharmacological action:

Anthocyanosides of bilberry (Vaccinium myrtillus L.) stimulate the synthesis and regeneration of rhodopsin, the photosensitive pigment of the retina, increasing its sensitivity to changes in light intensity, improves visual acuity and adaptation to the dark when light levels are low, improves blood supply to the retina.

Indications:

• myopia of high to medium
  
• acquired night blindness
  
• diabetic retinopathy
  
• violation of the mechanisms of adaptation to darkness (night and twilight vision)
  
• muscular asthenopia
  
• Central atherosclerotic degeneration of the retina Kunta-type-UNISA
  
• tapetoretinal abiotrophy of the retina (pigmentary degeneration of the retina).
  

Contraindications:

Individual hypersensitivity to the active substance or any auxiliary ingredients included in its composition.

Application of pregnancy and breast-feeding:

There is no reliable data on use during pregnancy and lactation. Therefore, the use is possible if the expected effect therapy outweighs the potential risk to the fetus or child.

Side effects:

Possible allergic reactions to the drug components.

Drug interactions:

Data on drug interaction with other drugs missing.

Method of application and dose:

Inside. 1 caps. 3 times a day. The course of treatment is 1 month.

Overdose:

Information about overdose are absent.

Special instructions:

There is no reliable data on the use of the drug in children. Therefore, the use is possible if the expected effect therapy outweighs the potential risk to the child.